Optison

Phase 2Small molecule

GGE Healthcare

Optison is one of 76 small molecule programs targeting Coronary Stenosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary StenosisActive, not recruiting

Heart Transplant RejectionActive, not recruiting

Carotid Artery DiseaseActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

LymphedemaActive, not recruiting

Coronary StenosisPreclinical

Active, not recruiting

Heart Transplant RejectionPreclinical

Active, not recruiting

Carotid Artery DiseasePhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

LymphedemaPhase 1

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Inlyta

PPrism Pharmaceuticals

Phase 3

27 5

Tecentriq

Roche

Phase 3

8 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 7

Imjudo

AstraZeneca

Phase 3

3 8

Imfinzi

AstraZeneca

Phase 3

2 9

TKI258

Novartis

Phase 3

1 10

Depo-Provera

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pediatric1 trial

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

Completed·GGE Healthcare·Phase 4·NCT03740997·39 enrolled

Renal Cell Carcinoma1 trial

Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation

Completed·TThomas Jefferson University·Phase 2·NCT02440334·53 enrolled

Coronary Stenosis1 trial

Detection of Coronary Stenosis With Intravenous Microbubbles

Withdrawn·UUniversity of Nebraska·N/A·NCT00580580

Kidney1 trial

IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?

Completed·MMayo Clinic·Phase 4·NCT02625428·40 enrolled

Heart Transplant Rejection1 trial

Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection

Terminated·—··NCT02300870·10 enrolled

7 more indications

Lymphedema1 trial

Contrast-Enhanced Ultrasound and Shear Wave Elastography for the Treatment of Lymphedema

Completed·MMayo Clinic·Phase 1·NCT05613946·10 enrolled

Resistance1 trial

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

Completed·GGE Healthcare·Phase 4·NCT00878878·30 enrolled

Echocardiography1 trial

Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE)

Withdrawn·UUniversity Hospital, Basel, Switzerland·Phase 1/2·NCT00286559

Carotid Artery Disease1 trial

Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease

Terminated·GGE Healthcare·Phase 2·NCT01394926·21 enrolled

Crohn's Disease1 trial

Contrast-Enhanced Ultrasound in Human Crohn's Disease

Withdrawn·UUniversity of Michigan·Phase 1/2·NCT02061163

Children1 trial

CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children

Completed·KKassa Darge·Phase 1/2·NCT02204917·31 enrolled

Patients With Solid Tumors1 trial

Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00186953·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Optison. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Optison compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Optison. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GE Healthcare company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGE Healthcare

Optison

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pediatric1 trial

Renal Cell Carcinoma1 trial

Coronary Stenosis1 trial

Kidney1 trial

Heart Transplant Rejection1 trial

Lymphedema1 trial

Resistance1 trial

Echocardiography1 trial

Carotid Artery Disease1 trial

Crohn's Disease1 trial

Children1 trial

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News